Skip to main content
SpringerLink
Log in

Treatment Options in Patients with Overactive Bladder: Initial and Pharmacological Management

  • Chapter
  • First Online:
Non-Neurogenic Bladder Dysfunctions

Part of the book series: Urodynamics, Neurourology and Pelvic Floor Dysfunctions ((UNPFD))

  • 356 Accesses

Abstract

Overactive bladder syndrome (OAB) is a common disorder with significant impact on quality of life. To date the first-line management options are lifestyle modification and the pharmacological treatment. However, it is daily experience that these patients are often not satisfied with therapies. This may result from a choice of the drug not ideal for the characteristics of the patient that requires its use, or it may result from the underestimation of the comorbidities, or frailties, of the patient. All this results in high abandonment of therapies and a mistrust in being able to see a solution to the symptoms of overactive bladder. This chapter describes lifestyle modification, the drugs available for the treatment of overactive bladder, and analyses numerous critical issues often found in patients with overactive bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACh:

Acetylcholine

BOO:

Bladder outlet obstruction

BPH:

Benign prostate hypertrophy

CNS:

Central nervous system

DO:

Detrusor overactivity

LUTS:

Lower urinary tract symptoms

MUI:

Mixed urinary incontinence

OAB:

Overactive bladder syndrome

QOL:

Quality of life

SUI:

Stress urinary incontinence

UI:

Urinary incontinence

UUI:

Urgency urinary incontinence

References

  1. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71–6.

    PubMed  PubMed Central  Google Scholar 

  2. Balzarro M, Rubilotta E, Mancini V, et al. Impact of overactive bladder-wet syndrome on female sexual function: a systematic review and meta-analysis. Sex Med Rev. 2019;7(4):565–74.

    Article  PubMed  Google Scholar 

  3. Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6(4):179–88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Abrams P, Cardozo L, Wagg A, Wein A. Adult conservative management. 6th International Consultation on Incontinence, Tokyo, September 2016. Incontinence 6th ed. Tokyo: Japanese Red Cross Medical Center; 2017. p. 1447–527.

    Google Scholar 

  5. Wyman J, Allen A, Hertsgaard L, Overson E, Allen S, Hatsukami D. Effect of smoking cessation on overactive bladder symptoms in adults: a pilot study. Neurourol Urodyn. 2014;33(6):866–7.

    Google Scholar 

  6. Wells MJ, Jamieson K, Markham TC, Green SM, Fader MJ. The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study. J Wound Ostomy Continence Nurs. 2014;41(4):371–8.

    Article  PubMed  Google Scholar 

  7. Robinson D, Hanna-Mitchell A, Rantell A, et al. Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn. 2017;36(4):876–81.

    Article  PubMed  Google Scholar 

  8. Milne JL. Behavioral therapies for overactive bladder. J Wound Ostomy Continence Nurs. 2008;35(1):93–101.

    Article  PubMed  Google Scholar 

  9. Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319–44.

    Article  CAS  Google Scholar 

  10. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243.

    Article  CAS  PubMed  Google Scholar 

  12. Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedeberg’s Arch Pharmacol. 2006;374(2):79.

    Article  CAS  Google Scholar 

  13. Kerbusch T, Wahlby U, Milligan PA, et al. M.O. population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003;56(6):639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cardozo L, Dixon A. Increased warning time with darifenacin:na new concept in the management of urinary urgency. J Urol. 2005;173(4):1214.

    Article  PubMed  Google Scholar 

  15. Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification Programme upon the symptoms of overactive bladder. Int J Clin Pract. 2008;62(4):606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98(5):1025.

    Article  CAS  PubMed  Google Scholar 

  17. Khullar V, Foote J, Seifu Y, Egermark M. Time-toeffect with darifenacin in overactive bladder: a pooled analysis. Int Urogynecol J. 2011;22(12):1573–80.

    Article  PubMed  Google Scholar 

  18. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, doubleblind, crossover study with tolterodine and darifenacin in healthy participants >=50 years. J Cardiovasc Pharmacol Ther. 2008;13(4):241–51.

    Article  CAS  PubMed  Google Scholar 

  19. Chancellor MB, Staskin DR, Kay GG, et al. Bloodbrain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259–73.

    Article  CAS  PubMed  Google Scholar 

  20. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel. Investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101(8):1036.

    Article  CAS  PubMed  Google Scholar 

  21. Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf. 2008;31(6):505.

    Article  CAS  PubMed  Google Scholar 

  22. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46(11):556–63.

    Article  CAS  PubMed  Google Scholar 

  23. Dell’utri C, Digesu GA, Bhide A, Khullar V. Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Int Urogynecol J. 2012;13:1337–44.

    Article  Google Scholar 

  24. Chapple C, Schneider T, Haab F, et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int. 2014;114(3):418–26.

    CAS  PubMed  Google Scholar 

  25. Wagg A, Oelke M, Angulo JC, Scholfield D, Arumi D. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients. Drugs Aging. 2015;32(2):103–25.

    Article  CAS  PubMed  Google Scholar 

  26. Murakami S, Yoshida M, Iwashita H, et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int. 2003;71(3):290–8.

    Article  CAS  PubMed  Google Scholar 

  27. Ohno T, Nakade S, Nakayama K, et al. Absolute bioavailability ofimidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol. 2008;65(2):197–202.

    Article  CAS  PubMed  Google Scholar 

  28. Kanayama N, Kanari C, Masuda Y, et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDPglucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica. 2007;37(2):139–54.

    Article  CAS  PubMed  Google Scholar 

  29. Kitagawa Y, Kuribayashi M, Narimoto K, et al. Immediate effect on overactive bladder symptoms following administration of imidafenacin. Urol Int. 2011;86(3):330–3.

    Article  CAS  PubMed  Google Scholar 

  30. Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agentimidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008;15(9):809–15.

    Article  CAS  PubMed  Google Scholar 

  31. Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008;15(11):986–91.

    Article  CAS  PubMed  Google Scholar 

  32. Sakakibara R, Hamano H, Yagi H. Cognitive safety and overall tolerability of imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study. Low Urin Tract Symptoms. 2014;6(3):138–44.

    Article  PubMed  Google Scholar 

  33. Thüroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16(Suppl 1):S48–61.

    Article  PubMed  Google Scholar 

  34. Swart PJ, Krauwinkel WJ, Smulders RA, et al. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2006;99(1):33.

    Article  CAS  PubMed  Google Scholar 

  35. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987.

    Article  CAS  PubMed  Google Scholar 

  36. Chapple CR, Rechberger T, Al-Shukri S, et al. YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the oncedaily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303.

    Article  CAS  PubMed  Google Scholar 

  37. Cardozo L, Amarenco G, Pushkar D, et al. SUNRISE Study Group. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013;111(5):804–10.

    Article  CAS  PubMed  Google Scholar 

  38. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48(3):464.

    Article  CAS  PubMed  Google Scholar 

  39. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204.

    Article  CAS  PubMed  Google Scholar 

  40. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615–26.

    Article  CAS  PubMed  Google Scholar 

  41. Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81.

    Article  CAS  PubMed  Google Scholar 

  42. Dmochowski R, Staskin DR. The Q-T interval and antimuscarinic drugs. Curr Urol Rep. 2005;6(6):405–9.

    Article  PubMed  Google Scholar 

  43. Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther. 1998;63:529.

    Article  CAS  PubMed  Google Scholar 

  44. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998;55:813.

    Article  CAS  PubMed  Google Scholar 

  45. Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008;9(7):1249.

    Article  CAS  PubMed  Google Scholar 

  46. Diefenbach K, Jaeger K, Wollny A, et al. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med. 2008;9(5):579.

    Article  PubMed  Google Scholar 

  47. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414.

    Article  PubMed  Google Scholar 

  48. Elinoff V, Bavendam T, Glasser DB, et al. Symptomspecific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006;60(6):745.

    Article  CAS  PubMed  Google Scholar 

  49. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007;81(3):377.

    Article  CAS  PubMed  Google Scholar 

  50. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701.

    Article  CAS  PubMed  Google Scholar 

  51. Geyer J, Gavrilova O, Petzinger E. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37(7):1371–4.

    Article  CAS  PubMed  Google Scholar 

  52. Allousi S, Laval K-U, Eckert R. Trospium chloride (Spasmolyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, nulticentre, placebo-controlled study. J Clin Res. 1998;1:439.

    Google Scholar 

  53. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, doubleblind, multicentre clinical trial. BJU Int. 2000;85(6):659.

    Article  CAS  PubMed  Google Scholar 

  54. Zinner N, Gittelman M, Harris R, et al. Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 Pt 1):2311.

    Article  CAS  PubMed  Google Scholar 

  55. Zinner NR, Dmochowski RR, Staskin DR, et al. Oncedaily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30(7):1214–9.

    CAS  PubMed  Google Scholar 

  56. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebocontrolled trials. Drugs Aging. 2011;28(2):151–60.

    Article  CAS  PubMed  Google Scholar 

  57. Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyloxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157:1093.

    Article  CAS  PubMed  Google Scholar 

  58. Andersson K-E, Chapple CR. Oxybutynin and the overactive bladder. World J Urol. 2001;19(5):319.

    Article  CAS  PubMed  Google Scholar 

  59. Amarenco G, Marquis P, McCarthy C, et al. Qualité de vie des femmes souffrant d’mpériosité mictionelle avec ou sans fuites: étude prospective aprés traitement par oxybutinine (1701 cas). Presse Med. 1998;27:5.

    CAS  PubMed  Google Scholar 

  60. Appell RA, Sand P, Dmochowski R, et al. Overactive bladder: judging effective control and treatment study group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001;76(4):358.

    Article  CAS  PubMed  Google Scholar 

  61. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168(2):580.

    Article  CAS  PubMed  Google Scholar 

  62. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23(4):263.

    Article  CAS  PubMed  Google Scholar 

  63. Davila GW, Daugherty CA, Sanders SW. A shortterm, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140.

    Article  CAS  PubMed  Google Scholar 

  64. Madersbacher H, Mürz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19:324.

    Article  CAS  PubMed  Google Scholar 

  65. Walter R, Ullmann C. Thummler et al. influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats. Drug Metab Dispos. 2003;31(6):714.

    Article  CAS  PubMed  Google Scholar 

  66. Stöhrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia—a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37:196.

    Article  PubMed  Google Scholar 

  67. Stöhrer M, Mürtz G, Kramer G, et al. Efficacy and tolerability of propiverine hydrochloride extendedrelease compared with immediate-release in patients with neurogenic detrusor overactivity. Spinal Cord. 2013;51(5):419–23.

    Article  PubMed  Google Scholar 

  68. Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol. 2006;13(6):692.

    Article  CAS  PubMed  Google Scholar 

  69. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol. 2000;37:702.

    Article  CAS  PubMed  Google Scholar 

  70. Igawa Y, Aizawa N, Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51(12):811–8.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Therapeutic Goods Agency (TGA). Australian public assessment report, (version date: 18-02-2014). https://www.tga.gov.au/auspar/auspar-mirabegron. Accessed 26 Feb 2015.

  72. van Gelderen EM, Li Q, Meijer J, et al. An exploratory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85:S88.

    Google Scholar 

  73. Serati M, Roberti Maggiore U, Sorice P, et al. Publication Committee of the Italian Society of Urodynamics. Is mirabegron equally as effective when used as first or second-line therapy in women with overactive bladder? Int Urogynecol J. 2017;28:1033–9.

    Article  PubMed  Google Scholar 

  74. Nitti V, Herschorn S, Auerbach S, et al. The efficacy and safety of mirabegron in patients with overactive bladder syndrome – results from a north-American phase III trial. Presented at the 26th annual congress of the European Association of Urology, Vienna, 18–22 Mar 2011.

    Google Scholar 

  75. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  76. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.

    Article  CAS  PubMed  Google Scholar 

  77. Batista JE, Kölbl H, Herschorns et al., BEYOND Study Group. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Natalin R, Reis LO, Alpendre C, et al. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2009;28:79–85.

    Article  PubMed  Google Scholar 

  79. Hillelsohn JH, Rais-Bahrami S, Bagadiya N, et al. Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy. Urol J. 2014;10(4):1114–8.

    PubMed  Google Scholar 

  80. Serati M, Andersson KE, Dmochowski R, et al. Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptoms. Eur Urol. 2019;75:129–68.

    Article  CAS  PubMed  Google Scholar 

  81. Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077.

    Article  PubMed  Google Scholar 

  82. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008;53:1021–8.

    Article  CAS  PubMed  Google Scholar 

  83. Hadiji N, Previnaire JG, Benbouzid R, Robain G, Leblond C, Mieusset R, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52(9):701–5.

    Article  CAS  PubMed  Google Scholar 

  84. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.

    Article  CAS  PubMed  Google Scholar 

  85. Hartman KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. Evid Rep Technol Asses. 2009;187:1–120.

    Google Scholar 

  86. Kato K, Furuhashi K, Suzuki K, et al. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595–7.

    Article  PubMed  Google Scholar 

  87. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749–67.

    Article  CAS  PubMed  Google Scholar 

  88. Sekeroglu MA, Hekimoglu E, Petricli IS, et al. The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479–82.

    Article  PubMed  Google Scholar 

  89. Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432–41.

    Article  CAS  PubMed  Google Scholar 

  90. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009;2009:CD004193.

    Google Scholar 

  91. Ostaszkiewic ZJ, Eustice S, Roe B, et al. Toileting assistance programmes for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2013;6:1–9.

    Google Scholar 

  92. Muderrisoglu AE, Becher KF, Madersbacher S, et al. Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf. 2019;18(10):915–23.

    Article  CAS  PubMed  Google Scholar 

  93. Shiota T, Torimoto K, Okuda M, et al. Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. Low Urin Tract Symptoms. 2020;12(1):54–61.

    Article  CAS  PubMed  Google Scholar 

  94. Malanowska E, Starczewski A, Bielewicz W, Balzarro M. Assessment of overactive bladder after laparoscopic lateral suspension for pelvic organ prolapse. Biomed Res Int. 2019, 2019:9051963.

    Google Scholar 

  95. Balzarro M, Rubilotta E, Porcaro AB. Long-term follow-up of anterior vaginal repair: a comparison among colporrhaphy, colporrhaphy with reinforcement by xenograft, and mesh. Neurourol Urodyn. 2018;37(1):278–83.

    Article  CAS  PubMed  Google Scholar 

  96. Inouye SK, et al. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

    Matteo Balzarro & Alessandro Antonelli

Authors
  1. Matteo Balzarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Antonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Balzarro .

Editor information

Editors and Affiliations

  1. Department of Urology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

    Matteo Balzarro

  2. Unit of Minimally Invasive, Robotic Urologic Surgery and Kidney Transplantation, Department of Experimental Medicine, Careggi Hospital, University of Florence, Florence, Italy

    Vincenzo Li Marzi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Balzarro, M., Antonelli, A. (2021). Treatment Options in Patients with Overactive Bladder: Initial and Pharmacological Management. In: Balzarro, M., Li Marzi, V. (eds) Non-Neurogenic Bladder Dysfunctions. Urodynamics, Neurourology and Pelvic Floor Dysfunctions. Springer, Cham. https://doi.org/10.1007/978-3-030-57393-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57393-5_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57392-8

  • Online ISBN: 978-3-030-57393-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation